作為基因治療產(chǎn)業(yè)領(lǐng)域的開(kāi)拓者，賽百諾及其自主研制開(kāi)發(fā)的產(chǎn)品“重組人p53腺病毒注射液,今又生(Gendicine®) 自誕生以來(lái)，作為中國(guó)自主創(chuàng)新的重要代表和民族高科技產(chǎn)業(yè)迎頭趕上西方的里程碑，在震動(dòng)世界的同時(shí)，更受到了包括時(shí)代周刊、美國(guó)商業(yè)周刊、Nature、Journal of Clinical Oncology、Biopharm International、《新英格蘭醫(yī)學(xué)雜志》、CCTV新聞聯(lián)播、人民日?qǐng)?bào)、新華社等國(guó)內(nèi)外頂尖新聞及醫(yī)學(xué)媒體的強(qiáng)烈、持久關(guān)注和報(bào)道。
As a leader and innovator in gene therapy, Sibiono and its innovative product Gendicine®, ‘rAd-p53, Inj' has been regarded as an important representative innovative product and symbolic as a milestone in the catching up with the West. The shocking news spread around the world and was enthusiastically reported in the famous news media and professional journals: ‘Time’, ‘Nature’, ‘Journal of Clinical Oncology’, ‘Biopharm International’, ‘New England Journal of Medicine’, CCTV-China Central Television, ‘People’s Daily’, ‘XinHua News Agency’.

                                    

人民日?qǐng)?bào)                                 中央電視臺(tái)                                   新華社                                      福布斯

                                   

        商業(yè)周刊                                  時(shí)代周刊                                華爾街日?qǐng)?bào)                           美國(guó)有限電視新聞網(wǎng)

                            

   英國(guó)廣播公司                        紅鯡魚(yú)                       國(guó)際生物制藥                     英國(guó)自然雜志

新英格蘭醫(yī)學(xué)雜志                  國(guó)際腫瘤基因治療學(xué)會(huì)           美國(guó)臨床腫瘤雜志                  深圳衛(wèi)視

 深圳特區(qū)報(bào)                               深圳新聞網(wǎng)